Enrollment started September 2016

TACT (TULSA-PRO® Ablation Clinical Trial) is a prospective, single-arm pivotal clinical study of 110 patients aimed at further evaluating the safety and efficacy of TULSA-PRO® to ablate prostate tissue in patients with localized, organ-confined prostate cancer.

Additional Information

For additional information on the TACT trial including eligibility criteria and clinical trial locations:

Multiple sites throughout the United States, Canada and Europe will participate in this trial.

TACT Clinical Trial Locations

  1. Western University, London Health Sciences Centre
  2. Sunnybrook Health Sciences Centre
  3. William Beaumont Hospital
  4. Johns Hopkins Hospital
  5. Vanderbilt University Medical Center
  6. University of Chicago Medical Center
  7. Indiana University Hospital
  8. University of Texas Southwestern Medical Center
  9. UCLA Health
  10. Heidelberg University/German Cancer Research Institute (DKFZ)
  11. University of Cologne
  12. Radboud University Medical Center
  13. Clinica Universidad de Navarra (CUN)
  14. ResoFus Alomar